Jiang Tao, Zhou Yuren, Zhu Jianming, Chen Zhuxi, Sun Peng, Zhang Qiang, Wang Zhen, Shao Qiang, Jiang Xiangrui, Li Bo, Wang Heyao, Zhu Weiliang, Shen Jingshan
Drug Discovery and Design Center, Key Laboratory for Receptor Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.
Arch Pharm (Weinheim). 2015 Jun;348(6):399-407. doi: 10.1002/ardp.201500082. Epub 2015 Apr 14.
The optimization of a series of fused β-homophenylalanine inhibitors of dipeptidyl peptidase-4 (DPP-4) is described. Modification on the P2-binding moiety of 6 (IC50 = 10 nM) led to the discovery of β-homophenylalanine derivatives containing pyrrolidin-2-ylmethyl amides. The introduction of a sulfamine in the meta position of the phenyl ring improved the potency against DPP-4 (6-12-fold increase). Compound 14k showed DPP-4 inhibitory activity with an IC50 value of 0.87 nM. Meanwhile, in vivo experiments exhibited that 14h had an efficiency comparable to sitagliptin at the dose of 10 mg/kg.
本文描述了一系列二肽基肽酶-4(DPP-4)的稠合β-高苯丙氨酸抑制剂的优化过程。对6(IC50 = 10 nM)的P2结合部分进行修饰,发现了含吡咯烷-2-基甲基酰胺的β-高苯丙氨酸衍生物。在苯环间位引入磺胺基提高了对DPP-4的活性(增加了6至12倍)。化合物14k表现出DPP-4抑制活性,IC50值为0.87 nM。同时,体内实验表明,14h在10 mg/kg剂量下的效果与西他列汀相当。